Journal article

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Cheng Peng, Alastair G Stewart, Owen L Woodman, Rebecca H Ritchie, Cheng Xue Qin

Frontiers in Pharmacology | FRONTIERS MEDIA SA | Published : 2020


Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease (NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of NAFLD patients are estimated to have NASH. NASH is typically characterized by liver steatosis inflammation, and fibrosis driven by metabolic disruptions such as obesity, diabetes, and dyslipidemia. NASH patients with significant fibrosis have increased risk of developing cirrhosis and liver failure. Currently, NASH is the second leading cause for liver transplant in the United States. More importantly, the risk of developing hepatocellular carcinoma from NASH has also been highlighted in recent studies. Patients may have ..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC) of Australia

Funding Acknowledgements

This work was supported in part by the CASS Foundation (CXQ), Victoria Medical Acceleration Grant (RHR), and the Victorian Government's Operational Infrastructure Support Program. RHR was supported by the National Health and Medical Research Council (NHMRC) of Australia (ID1059960, ID1158013), and CXQ is Australia National Heart Foundation Future Fellow. Victorian Medical Research Acceleration Fund (RR, CXQ, AGS).